As a result of the acquisition, Cynosure shares will cease to be traded on NASDAQ. Medical equipment manufacturer Hologic has successfully acquired medical aesthetics and technology provider Cynosure. Hologic made the acquisition whilst divesting its blood screening business. Approximately 70.6% of Cynosure shares were sold to Hologic. The financial ramifications of the acquisition will be discussed on 10 May 2017 when the company presents its results for the second fiscal quarter of 2017.
Medical equipment manufacturer Hologic has successfully acquired medical aesthetics and technology provider Cynosure. Hologic made the acquisition whilst divesting its blood screening business. Approximately 70.6% of Cynosure shares were sold to Hologic. The financial ramifications of the acquisition will be discussed on 10 May 2017 when the company presents its results for the second fiscal quarter of 2017.